Showing 1 - 5 results of 5 for search 'Giuseppe Fornarini', query time: 0.02s Refine Results
  1. 1
    Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau”

    Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau” by Sara Elena Rebuzzi, Giuseppe Fornarini, Alessio Signori, Pasquale Rescigno, Giuseppe Luigi Banna, Sebastiano Buti

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab

    The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab by Giulia Claire Giudice, Sara Elena Rebuzzi, Giulia Mazzaschi, Federica Pecci, Michele Maffezzoli, Alessandro Acunzo, Letizia Gnetti, Enrico Maria Silini, Giuseppe Caruso, Elena Rapacchi, Pasquale Rescigno, Giuseppe Fornarini, Giuseppe Luigi Banna, Sebastiano Buti

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy

    Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy by Ria Nagpal MB, BCh, BAO, Marina Campione PhD, Sara Elena Rebuzzi MD, Lucia Fratino MD, Pasquale Rescigno MD, Sergio Bracarda MD, Davide Bimbatti MD, Ugo De Giorgi MD, Matteo Santoni MD, Fabio Calabrò MD, Mimma Rizzo MD, Alessio Signori PhD, Diana Giannarelli PhD, Giuseppe Fornarini MD, Umberto Basso MD, Giuseppe Luigi Banna MD

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study

    First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study by Giandomenico Roviello, Javier Molina-Cerrillo, Francesco Massari, Linda Cerbone, Ondrej Fiala, Giuseppe Fornarini, Fernando Sabino Marques Monteiro, Carlo Cattrini, Johannes Landmesser, Carlo Messina, Anca Zgura, Sara Elena Rebuzzi, Andrey Soares, Francesco Carrozza, Jawaher Ansari, Francesco Grillone, Zsófia Küronya, Lorena Incorvaia, Dipen Bhuva, Cinzia Ortega, Cecilia Nasso, Ravindran Kanesvaran, Ilaria Zampiva, Camillo Porta, Sebastiano Buti, Matteo Santoni

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study

    Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study by Camillo Porta, Francesco Massari, Tarek Taha, Enrique Grande, Maria T. Bourlon, Ravindran Kanesvaran, Umberto Basso, Javier Molina-Cerrillo, Teresa Alonso-Gordoa, Zin W. Myint, Giuseppe Fornarini, Thomas Buttner, Se Hoon Park, Yüksel Ürün, Ugo De Giorgi, Renate Pichler, Pasquale Rescigno, Tomas Buchler, Hana Studentova, Bohuslav Melichar, Jawaher Ansari, Veronica Mollica, Jakub Kucharz, Mimma Rizzo, Alessandro Rizzo, Ray Manneh Kopp, Sebastiano Buti, Fernando Sabino Marques Monteiro, Andrey Soares, Aristotelis Bamias, Matteo Santoni

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: